MARLBOROUGH, Mass.--(BUSINESS WIRE)--EXACT Sciences Corporation (NASDAQ: EXAS) announced the final results of its prospective, blinded, multi-center study of the Company’s Version 2 technology for stool-based DNA (sDNA) screening for colorectal cancer (CRC). The overall results of the study, which is the largest study of Version 2 technology to date, were statistically consistent with the interim findings published earlier this year. The final study results, which include 445 samples, have been submitted for presentation at a major gastroenterology meeting scheduled to be held in 2008.
